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ABSTRACT
Atopic dermatitis is a type of eczema characterized by chronic inflammation of
the skin, affecting millions of people worldwide. Resveratrol, a naturally occurring
stilbenoid, is widely believed to exhibit beneficial effects on a host of chronic diseases.
Although some previous studies have aimed to evaluate the effects of resveratrol on the
pathogenesis of atopic dermatitis, this relationship remains ill-defined. We have
previously established that mast cell activation, remodeling, and cellular infiltration in the
hypodermis all begin prior to the IgE-mediated immune response in an atopic dermatitis
mouse model, and that this early pathogenesis is directly related to an increase in local
levels of sphingosine-1-phosphate. We have found novel evidence that treatment with
transdermal resveratrol attenuates mast cell activation, perivascular cell infiltration,
thickening of the epidermis, and inflammatory chemokines relevant to early-phase atopic
dermatitis. We are currently evaluating the effect of resveratrol on local levels of
sphingosine-1-phosphate and the activity of sphingosine kinase 1, the major enzyme
responsible for its production. The results we have obtained thus far support our
hypothesis that resveratrol can attenuate the development of atopic dermatitis, enabling
future investigation of its efficacy as a treatment for the disease. We also intend to use
these results as a gauge to evaluate the effects of other related compounds on the
development of atopic dermatitis.
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INTRODUCTION
Resveratrol (RSV) is a naturally occurring stilbenoid most famously found in the
skin of grapes. It is widely believed to have a vast array of anti-carcinogenic, antiinflammatory, and antioxidative protective effects.1-3 RSV is thought to be responsible
for the “French paradox” which is characterized by lower incidence of cardiovascular
diseases with red wine consumption, regardless of diets which are typically high in fat.1
RSV has been shown to modulate different cellular processes including NAD+
metabolism via sirtuin 1 (SIRT-1) and poly ADP-ribose polymerase 1 (PARP-1)
pathways, carcinogenesis through the inactivation of cyclooxygenase (COX) proteins,
and the phosphorylation of sphingosine by sphingosine kinase 1 (SphK1).2,4-7 Although
these mechanisms have been subject to extensive research over the last two decades,
more recent studies have found conflicting evidence surrounding the efficacy of RSV as a
treatment in various disease models.8 One such conflict has arisen from several studies
conducted to examine RSV’s effects on modulating sphingosine-1-phosphate (S1P), a
sphingolipid metabolite with a role in initiating inflammatory responses in mast cells
(MC).5,7,9-11 We suggest this can be explained by variations in experimental design such
as routes of administration, dosing, vehicles, specific disease models, and genetic
differences in cell-lines and mice used.12-14 We previously established that S1P is an early
modulator of IgE-independent MC activation and skin remodeling in mice, after inducing
atopic dermatitis (AD) with ovalbumin (OVA).9 We used a similar experimental design
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for this study to determine the effect of RSV on S1P production and other presymptomatic signs of AD pathogenesis.
Multiple studies have shown that RSV can attenuate sphingosine kinase 1
(SphK1)-mediated phosphorylation of sphingosine to produce S1P, but none suggested a
specific mechanism of action.5,7 We hypothesize that RSV prevents translocation of
SphK1 from the cytoplasm to the cell membrane, which is required for its activation. We
propose that this occurs via direct acetylation of SphK1 by RSV in the cytoplasm, based
on molecular research done by Dr. Mathew.6 We anticipate that our pending results will
demonstrate inhibition of OVA-induced local skin S1P elevation after transdermal
application of RSV, preventing the subsequent changes we have previously characterized
during early-phase AD, thus averting progression to disease.9
As suggested by previous studies, the low bioavailability of RSV in vivo may
hinder its delivery in adequate concentrations, limiting its beneficial effects.12-14
However, other research has shown that delivery of higher RSV concentrations can have
adverse pro-inflammatory consequences.10,11 We have conducted experiments with two
different and physiologically relevant concentrations of topical RSV, and though related
research is scarce, one study suggests these doses may circumvent both of these
limitations.2
In addition to providing compelling evidence to support proof of concept, this
pilot study has established a standard model so that the results of subsequent research can
be accurately compared. In the future, we plan to observe the effect of RSV on the
development of AD in the presence of either of two demonstrated cofactors: nicotinamide
(NAM) and nicotinamide riboside (NR).6 We also plan to evaluate another compound
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closely related to RSV named pterostilbene (PTE). PTE research is very limited, but
some studies have suggested that it may have similar effects with higher bioavailability
than RSV.14-16
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CHAPTER 1. METHODS
1.1. Atopic Dermatitis Model
For all experimental groups in this study, we used a well-established AD mouse
model shown to bare similarity to the pathogenesis of AD in humans.9,17 The methods
established by our previous study were adapted to evaluate the development of AD in 812 week female wild-type C57Bl/6J mice. Six mice were assigned to each of our four
experimental groups using a simple randomization technique as previously reported (see
Table 1.1 for group designations).9
On Day 1, initial treatment solutions were prepared. First, RSV was dissolved in
100% ethanol (ETOH) to achieve its maximum soluble concentration of 50 mg/mL. This
solution was then diluted with 0.9% saline to obtain 2.5 mg RSV/mL 5% ETOH. To
obtain final solutions for RSV treated groups, this was either further diluted with 0.9%
saline or combined with OVA in 0.9% saline. For vehicle control groups, 5% ETOH was
either further diluted with 0.9% saline or combined with OVA in 0.9% saline. All
treatment solutions are shown in Table 1.1.
ETOH was used as a vehicle because physiologically relevant concentrations of
RSV are insoluble in inorganic solvents such as saline.2 By first dissolving RSV in
ETOH, we were able to maximize its stability and solubility.14,18 Previous research has
suggested that membrane permeability to trans-RSV is significantly higher than to cisRSV, and that the trans- conformation is only stable once diluted to lower
concentrations.6,13
4

Table 1.1. Experimental Group Designations.
Group
Saline and
Vehicle (SV)
OVA and
Vehicle (OV)
Saline and RSV
(SR)
OVA and RSV
(OR)

Day 1 Treatment
0.05% ETOH
100 µg OVA in 0.05% ETOH

Days 2-6 Treatment
0.05% ETOH

2.5 µg RSV in 0.05% ETOH

2.5 µg RSV in

100 µg OVA + 2.5 µg RSV in
0.05% ETOH

0.05% ETOH

5

For the application of Day 1 treatments, the upper-back areas of mice in each
group were shaved then tape-stripped three times. Next, 100 µL of designated treatment
solutions were pipetted onto 1 cm by 1 cm square gauze patches. The patches were then
applied to the shaved and tape-stripped area of each mouse. A half cm section of sterile
flexible tubing was then placed over the patch with one end over the center of the patch
and the other extending slightly past its caudal border. The tube and patch were then
secured with a Tegaderm transparent dressing so that the patch was completely covered,
and the caudal end of the tubing was flush with the edge of the Tegaderm. To ensure that
the patch and dressing remained in place, an adhesive bandage was applied over the
dressing and 1” of transparent tape was applied to the ends of the bandage.9 Shaving,
tape-stripping, and patching all occurred on Day 1 of the study.
On Days 2-6, all mice received the same treatments without OVA. Treatments
given on Days 2-6 are listed in Table 1.1. To apply these daily treatments, Day 1 patches,
taped bandages, and Tegaderm dressings were left in place to prevent unintended trauma
to the skin. 100 µL of the assigned treatment solution was pipetted through the flexible
tubing onto the patch.
On Day 7, mice were euthanized and the patches were removed. A 1 cm by 1 cm
skin sample was collected from the treated area and was then cut laterally into four equal
strips for histological, mRNA, and lipidomic analyses.9 All animal procedures were
performed in accordance with University of South Carolina Institutional Animal Care and
Use Committee approval and all methods used adhere to relevant guidelines and
regulations.
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1.2. Histology and Microscopy
Skin samples were fixed in 4% fresh paraformaldehyde, paraffin embedded,
sectioned, and mounted on microscopy slides by the University of South Carolina School
of Medicine’s Instrumentation Resource Facility. One slide from each sample was then
stained with hematoxylin and eosin (H&E) for measurement of skin layer thickness and
determination of cellular infiltration, and another was stained with methylene blue (MB)
for MC quantification and MC activation status.
H&E slides were stained by the University of South Carolina School of
Medicine’s Instrumentation Resource Facility. Tagged image file format (TIFF) images
of these slides were obtained using a Nikon E-600 microscope with Micropublisher
camera and software at 10x magnification. Cellular infiltration of the hypodermis was
quantified using MetaMorph 6.1 software and previously reported morphometric
parameters.9 Skin layer thickness was calculated using the same software and a
morphometric measurement technique recently adapted by our lab for this purpose.21 The
investigators who performed this analysis and all subsequent quantifications were singleblinded to slide group designations.
For MB staining, slides were prepared by deparaffinization and rehydration.
Slides were then placed in 0.05% MB for five seconds, rinsed with water, dehydrated in
100% ETOH, and mounted under coverslips with cytoseal 60.9,19 These sections were
then imaged using a Nikon E-600 microscope with Micropublisher camera and software
to obtain TIFF images at 40x magnification. These images were analyzed with
MetaMorph 6.1 software to quantify MCs and detect MC degranulation using
morphometric parameters previously published by our lab.9,20
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1.3. Morphometric Measurement of Skin Remodeling
The epidermal, dermal, and hypodermal thickness of each H&E stained sample
was measured using a morphometric measurement technique recently adapted by our
lab.21 Three to six images were obtained per animal at 10x magnification, then three
regions of interest (ROI) were randomly selected for each skin layer per image. 9,20
MetaMorph 6.1 software was used to trace the perimeter of the target skin layer in each
ROI. The software provided measurements for the traced area (TA) and its perimeter
(PR). This TA was treated as an irregular two-dimensional fiber and the equation below
was used to calculate the average thickness, or breadth, of each fiber.21
Fiber Breadth (FB) = ¼ [PR - (PR2 – 16TA)1/2]
FB measurements were compiled to determine the average thickness of the
epidermis, dermis, and hypodermis for each experimental group. This method is depicted
in Figure 1.1.
1.4. Computer Assisted Quantification of Hypodermal Cellular Infiltration
To quantify hypodermal cellular infiltration, we used an imaging method
previously developed and published by our lab.9,20 At least 10 images per animal were
collected from H&E stained slides and analyzed using MetaMorph 6.1 software. The
distinct blue color of hematoxylin-stained nuclei was identified using the hue, saturation,
and intensity (HSI) color model through a process called thresholding.20 To eliminate
background, areas that met this color threshold were further analyzed using
morphometric parameters to exclude any which were not consistent with previously
defined size and shape characteristics of nuclei.9,20 The software analyzed images using a
circular ROI with a fixed diameter (75 µm) which was moved to survey the entire
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Figure 1.1. Morphometric Measurement of Skin Layer Thickness.
[A] is an image obtained from an H&E stained slide at 10x magnification. The portion of
the image outlined in white was selected as an ROI for measurement of the epidermis.
[B] represents the tracing and isolation of the epidermis from the ROI depicted in [A] to
produce an irregular fiber using MetaMorph software. The software produced values to
quantify the TA (orange) in µm2 and the PR (blue) in µm of the fiber. This representation
is enlarged for figure clarity.
[C] displays the equation used to calculate the FB of the fiber shown in [B]. For our
purposes, this equation essentially converts the irregular fiber [B] into a rectangle [D]
while preserving original length to width ratio.
[D] shows that the FB (purple), or width of the final object represents the average
thickness of the epidermis. This method was used to calculate average thickness values
for all skin layers.
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hypodermis in each image. The software then quantified the number of nuclei present in
each ROI and the average number of nuclei per ROI was calculated by group.9
1.5. In situ Determination of Mast Cell Degranulation
Our lab has previously shown that morphometric parameters can be used to
describe the cytoplasm of MCs and define MC activation status.20 For this analysis, 15
adjacent images of the dermis and hypodermis were recorded as TIFF files from each MB
stained slide at 40x magnification. MCs in each image were then identified as individual
ROI using the HSI color model thresholding routine of MetaMorph 6.1.20 HSI values
were set to isolate the unique cytoplasmic blue/purple color of MB stained MCs. The
software’s integrated morphometry routine was then used to measure the area and
integrated optical density (IOD) of each thresholded ROI.20 IOD values represent the
total amount of material present in the ROI. The IOD of each ROI was then divided by its
area and the resulting values were used to identify whether MCs were intact or
degranulated, as previously reported.9,20 The average number of intact MCs, degranulated
MCs, and total MCs present in each experimental group were then calculated, analyzed
for significance, and compared.9
1.6. Quantitative Reverse Transcription Polymerase Chain Reaction Assay
One strip from each skin sample was designated for analysis by quantitative
reverse transcription polymerase chain reaction assay (qRT-PCR). These stripss were
snap-frozen immediately after collection and stored at -80°C until RNA extraction. Total
RNA was isolated from each sample with the miRNeasy kit from Qiagen using the
manufacturer’s protocol. The Bioline cDNA synthesis kit and protocol were used to
reverse transcribe cDNA from the isolated RNA. QPCR was performed using the Bioline
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SYBR No-ROX kit with Bio-Rad CFX Connect equipment and software. We analyzed
target gene mRNA expression for chemokines CCL2, CCL3 and CCL5, as well as
FcƐRIα and SphK1, relative to reference genes ß-2-microglobulin (B2M) and ß-actin
(BA). GAPDH was considered as a reference gene but was excluded from data analysis
because its expression between samples was less consistent than B2M and BA. All
primer sequences are listed in Table 1.2. QPCR conditions were set to the following, as
previously reported: 95°C for 10 minutes during the initial step, followed by 40 repeating
cycles of 95°C for 10 seconds, annealing at 55°C for 20 seconds, and extension at 72°C
for 15 seconds.9,22 All reactions were performed in duplicate and repeated once. Data was
normalized to both reference genes independently and fold-change was determined based
on vehicle-control values. A total of eight fold-change values were obtained per animal
(48 per experimental group) and outliers were excluded using GraphPad Prism 7.0
software. This software was then used to calculate average fold-change and standard
error of the mean (SEM) by group.
1.7. Statistics
For all quantifications, outliers were excluded using GraphPad Prism 7.0
software. This software was then used to perform a one-way analysis of variance
(ANOVA) with multiple comparisons to identify statistically significant differences
between groups for all quantifications. Differences were considered significant for
probability values (P) less than 0.05. GraphPad Prism 7.0 software was used to create all
bar graphs. All treatment group results were compared against the SV (vehicle control)
group since we have not yet included a true negative control group in this study. All qRT-
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Table 1.2. qRT-PCR Primer Sequences.
Gene
B2M
BA
CCL2
CCL3
CCL5
FcƐRIα
SphK1

Forward (F)
Reverse (R)
F
R
F
R
F
R
F
R
F
R
F
R
F
R

5’

Primer Sequence

3’

CCGAACATACTGAACTGCTACGTAA
CCCGTTCTTCAGCATTTGGA
GACGGCCAGGTCATCACTATTG
AGGAAGGCTGGAAAAGAGCC
CACTCACCTGCTGCTACTCA
GCTTGGTGACAAAAACTACAGC
GCCATATGGAGCTGACACCC
TAGTCAGGAAAATGACACCTGGC
TGCCCTCACCATCATCCTCACT
GGCGGTTCCTTCGAGTGACA
ATTGTGAGTGCCACCGTTCA
GCAGCCAATCTTGCGTTACA
CGTGGACCTCGAGAGTGAGAA
AGGCTTGCTAGGCGAAAGAAG
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PCR analyses were performed in duplicate and each experimental group consisted of 6
mice treated in two independent trials. Data collection is not yet complete for some
histological analyses and all variations in sample size are clearly reported.

13

CHAPTER 2. RESULTS & DISCUSSION
2.1. Resveratrol Attenuates Remodeling of the Epidermis During Early-Phase
Atopic Dermatitis
Consistent with our previous work with this murine AD model, we found
significant thickening of the epidermis and dermis one week after a single exposure to
OVA in the group that did not receive treatment with RSV (OV) compared to the vehicle
control group (SV).9 As shown in Figure 2.1A, average thickening of the epidermis was
significantly reduced in the group that was exposed to OVA and treated daily with RSV
(OR) compared to the OV group. This finding suggests that RSV prevents remodeling of
the epidermis during the development of AD.
We have not seen evidence suggesting that RSV has the same ameliorative effect
on thickening of the dermis during early-phase AD (Figure 2.1B). However, this may be
explained by the fact that we have analyzed six images per animal for measurement of
the epidermis, but only three images per animal for the dermis. The cause of this anomaly
is not likely to be an inability of RSV to reach the dermis because cellular infiltration of
the hypodermis was significantly attenuated after RSV treatment.
Consistent with our previously reported findings, we did not observe any
significant thickening of the hypodermis one week after exposure to OVA (Figure 2.1C).9
Although we did observe significantly increased cellular infiltration in the hypodermis, it
does not seem to cause any significant thickening of this skin layer at this early stage of
AD pathogenesis.9 While skin layer thickness is an important indicator of AD, cellular
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A

B

C

Figure 2.1. Skin Layer Thickness.
[A] RSV attenuated OVA-induced thickening of the epidermis. N=3, 6 images per
animal, 3 ROI per image. OV>OR, P<0.001. OV>SV, P=0.025. OV>SR, P=0.014.
OR=SV, P=0.266. SR=SV, P=0.387. SR=OR, P=0.175.
[B] RSV had no significant effect on OVA-induced thickening of the dermis. N=3, 3
images per animal, 3 ROI per image. OV=OR, P=0.615. OV>SV, P=0.040. OV>SR,
P=0.007. OR=SV, P=0.484. SR=SV, P=0.930. SR=OR, P=0.186.
[C] Neither RSV nor OVA exposure had a significant effect on thickening of the
hypodermis. N=3, 3 images per animal, 3 ROI per image. OV=OR, P=0.859. OV=SV,
P=0.939. OV=SR, P=0.462. OR=SV, P=0.527. SR=SV, P=0.811. SR=OR, P=0.119.
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infiltration of the hypodermis likely begins before thickening of any skin layer can be
detected.
2.2. Hypodermal Cellular Infiltration is Reduced by Treatment with Resveratrol
Using morphometric parameters we have previously defined, we were able to
quantify cellular infiltration of the entire area of the hypodermis mounted on each H&E
stained slide.9,20 The number of nuclei identified in each ROI were compiled according to
experimental group designation and group averages were compared. A separate
quantification of the number of nuclei present in each ROI which contained blood vessels
(BV) was also performed and data from both quantifications of hypodermal cellular
infiltration is displayed in Figure 2.2.
As we observed previously, both whole hypodermal and perivascular cellular
infiltration were significantly increased one week after a single exposure to OVA.9 The
magnitude of this OVA-induced cellular infiltration was significantly decreased after
daily treatment with RSV, both in the whole hypodermis and near hypodermal blood
vessels specifically. These findings indicate that RSV can prevent the development of
AD by reducing the recruitment of cells likely to contribute to early inflammation and
tissue remodeling. Although these significant increases in hypodermal cellular infiltration
for OVA exposed groups is significant, hypodermal thickening may not be observed until
longer-term effects of this infiltration occur.
2.3. Mast Cell Activation is Attenuated by Resveratrol
We used our previously described morphometric method to determine the average
total number of MCs, intact MCs, and degranulated (or activated) MCs per mm2 of skin
tissue for each treatment group. As shown in Figure 2.3A, we did not observe any

16

A

B

Figure 2.2. Hypodermal Infiltration.
[A] RSV significantly decreased OVA-induced cellular infiltration in the whole
hypodermis. N=6, 10 images per animal, 10 ROI per image, 600 ROI per group.
OV>OR, P<0.0001. OV>SV, P<0.0001. OV>SR, P<0.0001. OR>SV, P<0.0001. SR=SV,
P=0.0713. OR>SR, P<0.0001.
[B] RSV significantly decreased OVA-induced cellular infiltration around BV in the
hypodermis. N=6, 10 images per animal, only ROI from [A] containing BV included,
225-255 ROI per group. OV>OR, P<0.0001. OV>SV, P<0.0001. OV>SR, P<0.0001.
OR>SV, P<0.0001. SR=SV, P=0.0804. OR>SR, P<0.0001.
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B

FcƐRIα mRNA Fold Change

A

C

D

Figure 2.3. Activity of Mast Cells and Sphingosine Kinase 1.
[A] Neither OVA exposure nor treatment with RSV had a significant effect on the mean
number of all MCs. N=3, 15 images per animal. OV=OR, P=0.281. OV=SV, P=0.342.
OV=SR, P=0.145. OR=SV, P=0.561. SR=SV, P=0.263. OR=SR, P=0.344.
[B] RSV prevented OVA-induced MC degranulation. N=3, 15 images per animal.
OV>OR, P=0.008. OV>SV, P=0.033. OV=SR, P=0.251. OR=SV, P=0.875. SR=SV,
P=0.734. OR=SR, P=0.371.
[C] RSV significantly decreased OVA-induced upregulation of FcƐRIα mRNA. N=6, 8
fold-change values calculated per animal, 48 fold-change values per group. OV>OR,
P=0.0355. OV>SV, P<0.0001. OV>SR, P<0.0001. OR>SV, P<0.0001. SR=SV,
P=0.1098. OR>SR, P=0.0009.
[D] Neither OVA exposure nor treatment with RSV had a significant effect on SphK1
mRNA expression. N=6, 8 fold-change values calculated per animal, 48 fold-change
values per group. OV=OR, P=0.5364. OV=SV, P=0.1621. OV=SR, P=0.2709. OR<SV,
P=0.0041. SR=SV, P=0.9929. OR<SR, P=0.0100.
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significant differences in the average number of MCs per mm2 between groups. However,
Figure 2.3B demonstrates significantly increased MC degranulation one week after
exposure to OVA and that this increase in degranulation was attenuated after RSV
treatment.
As shown in Figure 2.3C, FcƐRIα mRNA expression was significantly increased
one week after OVA exposure and this increase was ameliorated after treatment with
RSV. FcƐRIα is the alpha chain of the high affinity IgE receptor. FcƐRIα expression in the
skin is effectively exclusive to MCs and we have previously shown that its relative
mRNA expression correlates to the local abundance of MCs.9,24 It is possible that RSV
decreases expression of FcƐRIα by MCs, making them less susceptible to IgE-mediated
activation. However, further work is needed to reconcile the discrepancies between this
data and the results of our histological quantification of MCs.
Figure 2.3D shows that we found no significant differences in SphK1 mRNA
expression between groups. This result neither supports nor weakens our hypothesis that
RSV reduces the activity of SphK1. Since we suggest RSV works by preventing the
translocation of SphK1 to the cell membrane to reach its substrate, its mRNA expression
may not be affected.
2.4. Treatment with Resveratrol Decreases mRNA Expression of Inflammatory
Chemokines
We have previously shown that CCL2, CCL3 and CCL5 are significant
contributors to allergic airway and AD skin inflammation.9,24 Based on our previous
research, we know that OVA exposure promotes the expression of these chemokines.9
The results of our current work are consistent with our previous findings, except that we
found no significant increase in CCL3 mRNA expression after OVA exposure. However,
19

this previously reported increase was significantly less than the increases observed in
CCL2 and CCL5 mRNA. In support of our hypothesis, we have found that mRNA
expression for both CCL2 and CCL5 were significantly decreased in the OVA exposed
group that was treated with RSV, compared to the OVA exposed group that did not
receive treatment. This is consistent with the RSV-mediated decrease in hypodermal
cellular infiltration we observed because these chemokines are responsible for immune
cell recruitment. This data is displayed in Figure 2.4.
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Figure 2.4. Chemokine mRNA Expression.
[A] RSV prevented OVA-induced upregulation of CCL2 mRNA expression. N=6, 8 foldchange values calculated per animal, 48 fold-change values per group. OV>OR,
P<0.0001. OV>SV, P<0.0001. OV>SR, P<0.0001. OR=SV, P>0.9999. SR=SV,
P=0.9910. OR=SR, P=0.9883.
[B] Neither OVA exposure nor treatment with RSV caused a significant change in the
mRNA expression of CCL3. N=6, 8 fold-change values calculated per animal, 48 foldchange values per group. OV=OR, P>0.9999. OV=SV, P=0.7346. OV=SR, P=0.4175.
OR=SV, P=0.7225. SR=SV, P=0.9439. OR=SR, P=0.4060.
[C] RSV prevented OVA-induced upregulation of CCL5 mRNA expression. N=6, 8 foldchange values calculated per animal, 48 fold-change values per group. OV>OR,
P<0.0001. OV>SV, P=0.0123. OV>SR, P=0.0003. OR=SV, P=0.0604. SR=SV,
P=0.2252. OR=SR, P=0.9312.
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CHAPTER 3. FUTURE DIRECTIONS
3.1. Implications
The goals of this pilot study were to determine if topical application of RSV: 1)
has any effect on early IgE independent S1P elevation, MC activation, chemokine
expression, cellular infiltration, as well as remodeling of skin tissue, and 2) affects the
translocation of SphK1 to the cell membrane to reach its substrate. While this study is not
yet complete, we now have enough evidence to conclude that topical application of RSV
may serve as a prophylactic agent for AD. This conclusion serves as proof of our
concept, enabling us to proceed with related work in the future. We intend to use our
findings as standards for the evaluation of our upcoming research into effects of
alternative dosing, similar compounds, and RSV as a treatment for AD.
3.2. Ongoing Research
Although we have already found evidence to support several elements of our
hypothesis, we are still working to complete the picture. Our outstanding objectives
include determining: 1) how the effects of a lower dose of RSV differ from the dose we
have already investigated, 2) whether RSV attenuates the enzymatic activity of SphK1 by
preventing its translocation to the cell membrane, 3) if RSV affects local S1P levels, and
4) if our ETOH vehicle causes any effects.
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We have already completed another group of trials using a lower dose of RSV (1
µg), but we have not yet been able to perform data analysis of these samples. Once we
compare these results to those observed for the 2.5 µg treatment group, we will know if
we should evaluate higher or lower doses in future trials.
We are also currently working on localizing SphK1 at the subcellular level which
will allow us to determine if RSV alters the translocation of SphK1 to the cell membrane,
preventing it from reaching its substrate. Subcellular localization of SphK1 will be
accomplished by staining of slides with immunofluorescent antibodies and collecting
images via confocal microscopy. Slides will be deparaffinized and rehydrated before heat
induced antigen retrieval. Phalloidin conjugated with AlexaFuor™ (488 nm) will be used
for actin staining. Slides will then be treated with a rabbit anti-mouse anti-SphK1
antibody or an isotype-matched negative control antibody. We will then use a goat antirabbit Cy™ 3 (543nm) secondary antibody and mount slides using the
VECTASHIELD™ DAPI paramount medium. A confocal microscope and software will
be used to collect images to determine the cytoplasmic and membrane associated
distributions of SphK1. We anticipate that there will be more membrane associated
SphK1 in the MCs of animals exposed to OVA compared to vehicle controls, and that
this increase is attenuated by RSV treatment.
To strengthen our current results, we also plan to quantify local S1P via tissue
lipidomic analysis to determine whether this mediator of the early inflammatory response
is affected by RSV treatment. Tissue samples will be sent to the VCU Lipidomics Core
for analysis using liquid chromatography-electrospray ionization-tandem mass
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spectrometry, as previously reported.9 S1P quantities will be normalized to sample
weight, averaged by group, and analyzed for significant differences.
Prior to completing this pilot study, we will also perform another trial to ensure
that our ETOH vehicle does not have any unanticipated effects. This trial will be
performed using the previously described methods and will consist of a vehicle only
group, a vehicle and OVA group, a saline only group, and a saline and OVA group.
3.3. Investigation of the Dose-Response Relationship
As previously stated, the doses chosen for our initial evaluation of RSV were
selected based on their theorized biological relevance and limited related research. In
addition to these 2.5 µg and 1.0 µg doses, we plan to evaluate the effects of doses that are
either higher or lower depending on the results of our 1.0 µg trial to obtain a clearer
picture of RSV’s dose-response curve.
3.4. Related Compounds
Due to scarce research into resveratrol and pterostilbene alone or in combination
with NAM and NR cofactors with respect to chronic inflammatory diseases, this initial
study provided us with the data we will need to determine if these other compounds can
be at least as effective as resveratrol in the prevention of AD.
3.5. Resveratrol as a Treatment for Atopic Dermatitis
Since we have found that resveratrol can ameliorate several important effector
mechanisms of AD pathogenesis, we will investigate whether it can reverse ADassociated changes once they have already occurred using the same murine AD model.
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